US4853209A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bone marrow suppressing agents
Assignee: Dow Chemical Co
•
Filing: 1987-10-27
•
Granted: 1989-08-01
•
Expires: 2007-10-27
Abstract
Abstract The invention concerns a method for suppressing bone marrow which comprises administering at least one bone marrow suppressing radionuclide composition selected from the group of radionuclide compositions comprised of at least one of Samarium-153, Gadolinium-519, and Holmium-166 and at least one of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, nitrilotrimethylenephosphonic acid and tris(2-aminoethyl)aminehexamethylenephosphonic acid, or a physiologically acceptable salt thereof.
Inventors
- 👤 Donald A. Kaplan
- 👤 William F. Goeckeler
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 02:36
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0489; A61K51/0474; A61K51/0478; A61K2121/00
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
101 words
A method of suppressing bone marrow which causes partial or total eradication of the bone marrow for the treatment of diseases selected from the group consisting of leukemias, lymphomas, myelomas, Hodgkins disease and genetic disorders which comprises administering to a mammal in need of such treatment a bone marrow suppressing amount of at least one bond marrow suppressing composition comprising at least one radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, and Holmium-166 with at least one ligand selected from the group consisting of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, nitrilotrimethylenephosphonic acid and tris(2-aminoethyl)aminehexamethylenephosphonic acid, or a physiologically-acceptable salt thereof.
Claim 2
Independent Claim
101 words
A method of suppressing bone marrow which causes partial or total eradication of the bone marrow for the treatment of diseases selected from the group consisting of leukemias, lymphomas, myelomas, Hodgkins disease and genetic disorders which comprises administering to a mammal in need of such treatment a bone marrow suppressing amount of at least one bond marrow suppressing composition comprising at least one radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, and Holmium-166 with at least one ligand selected from the group consisting of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, nitrilotrimethylenephosphonic acid and tris(2-aminoethyl)aminehexamethylenephosphonic acid, or a physiologically-acceptable salt thereof.
Claim 3
Dependent Claim
16 words
The method of claim 1 wherein the ligand is ethylenediaminetetramethylenephosphonic acid or a physiologically-acceptable salt thereof.
Claim 4
Dependent Claim
16 words
The method of claim 1 wherein the ligand is hydroxyethylethylenediaminetrimethylenephosphonic acid or a physiologically-acceptable salt thereof.
Claim 5
Dependent Claim
21 words
The method of claim 1 wherein the radionuclide is Samarium-153 and the ligand is ethylenediaminetetramethylenephosphonic acid or a physiologically-acceptable salt thereof.
Claim 6
Dependent Claim
21 words
The method of claim 1 wherein the radionuclide is Samarium-153 and the ligand is hydroxyethylethylenedia acid or a physiologically-acceptable salt thereof.
Claim 7
Dependent Claim
21 words
The method of claim 1 wherein the radionuclide is Samarium-153 and the ligand is diethylenetriaminepentamethylenephosphonic acid or a physiologically-acceptable salt thereof.
Claim 8
Dependent Claim
21 words
The method of claim 1 wherein the radionuclide is Holmium-166 and the radionuclide is ethylenediaminetetramethylenephosphonic acid or a physiologically-acceptable salt thereof.
Claim 9
Dependent Claim
21 words
The method of claim 1 wherein the radionuclide is Gadolinium-159 and the ligand is ethylenediaminetetramethylenephosphonic acid or a physiologically-acceptable salt thereof.
Claim 10
Dependent Claim
43 words
The method of claim 1 used in conjunction with an additional treatment regimen using at least one of (a) one or more bone marrow suppressing agents, and/or (b) one or more chemotherapeutic agents, and/or (c) one or more radiotherapeutic agents or radiotherapeutic methods.
Claim 11
Dependent Claim
16 words
The method of claim 1 used in conjunction with total body irradiation or targeted external irradiation.
Claim 12
Dependent Claim
20 words
The method of claim 1 including the additional step of bone marrow transplantation after sufficient bone marrow suppression is achieved.
Claim 13
Dependent Claim
24 words
The method of claim 1 used in conjunction with one or more therapeutic regimens for the treatment of leukemia, lymphoma, myeloma or Hodgkin's disease.
Claim 14
Dependent Claim
13 words
The method of claim 12 wherein the disease being treated is a leukemia.
Claim 15
Dependent Claim
13 words
The method of claim 12 wherein the disease being treated is a lymphoma.
Claim 16
Dependent Claim
13 words
The method of claim 12 wherein the disease being treated is a myeloma.
Claim 17
Dependent Claim
13 words
The method of claim 12 wherein the disease being treated is Hodgkin's disease.
Claim 18
Dependent Claim
17 words
The method of claim 1 used in conjunction with a treatment employing at least one chemotherapeutic agent.
Claim 19
Dependent Claim
21 words
The method of claim 17 wherein the chemotherapeutic agent is selected from dimethyl busulfan, cyclophosphamide, bischloroethyl nitrosourea, cytosine arabinoside, and 6-thioguanine.
Claim 20
Dependent Claim
22 words
The method of claim 1 used in conjunction with total body irradiation and with a treatment employing at least one chemotherapeutic agent.
Claim 21
Dependent Claim
21 words
The method of claim 19 wherein the chemotherapeutic agent is selected from dimethyl busulfan, cyclophosphamide, bischloroethyl nitrosourea, cytosine arabinoside, and 6-thioguanine.
References Cited (Backward Citations)
US3965254A
Cited
US4017595A
Cited
US4054645A
Cited
US4232000A
Cited
US4385046A
Cited
EP0164843A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-31 | 1993-01-30 | 1993-08-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-31 | 1997-01-30 | 1997-08-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-31 | 2001-01-30 | 2001-08-01 | $7700.00 | Window Closed / Lapsed |